IndiaTimes
A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by mid-2026. Developed by Gilead Sciences, it’s the first PrEP medication requiring only two doses annually. While approved in Canada for treatment in 2022, it’s now under review for prevention…
Read More
Lenacapavir HIV shot approved in US may enter Canada by 2026; just two injections needed a year
Michele Michaud
07:22
A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by mid-2026. Developed by Gilead Sciences, it’s the first PrEP medication requiring only two doses annually. While approved in Canada for treatment in 2022, it’s now under review for prevention…
